1. Scrip
  2. >>Business

CureVac Enlists Bayer To Secure Place Among COVID-19 Vaccines ‘Second Wave’

Company Faces Competition From J&J, Novavax

 
• By Andrew McConaghie

While demand for COVID-19 vaccines will be huge for the next two years, only those players with major manufacturing and commercial infrastructures in place will play a big role.

Bayer, Wuppertal
German neighbors Bayer will provide big pharma resources to support CureVac's push to bring its COVID-19 vaccine to market in 2021. • Source: Ina Fassbender/AFP via Getty Images

For smaller companies aiming to take part in the ‘second wave’, time is running out to establish themselves as credible – and profitable – suppliers of COVID-19 vaccines.

One such company, CureVac, and has now enlisted German compatriots Bayer to help provide the scale and breadth of resources needed

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip